- Home
- IMRN
IMRN
Immuron Limited
as 11-15-2024 4:00pm EST
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.0M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 6.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.59 - $5.96 | Next Earning Date: | 11-26-2024 |
| Revenue: | $3,271,194 | Revenue Growth: | 171.67% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immuron Limited News
IMRN Breaking Stock News: Dive into IMRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 days ago
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
GlobeNewswire
a month ago
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
GlobeNewswire
a month ago
Immuron Travelan® continued strong sales growth
MT Newswires
a month ago
Immuron Says US Navy Completes Interim Analysis of Drug for Campylobacter, Enterotoxigenic Escherichia Coli
GlobeNewswire
a month ago
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
Simply Wall St.
a month ago
Immuron Full Year 2024 Earnings: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)
GlobeNewswire
2 months ago
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now
MT Newswires
2 months ago
Immuron Plans Phase 2 Trial for IMM-529 Following Positive US FDA Feedback
Compare IMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRN Immuron Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.